Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risperdal CONSTA for prevention of mood episodes in bipolar I disorder
2004-003781-14Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Oct 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of risperidone in bipolar I disorder (3 arms), sponsored by Johnson & Johnson. Primary endpoint: Time to relapse of mood episode. Started Oct 2004; status: completed.
02
Drugs
risperidone
03
Conditions
bipolar I disorder
Beyond the preview
Go deeper on 2004-003781-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-003781-14.